Research presented at the 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) has highlighted a complex relationship between glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, and musculoskeletal health. While these medications provide clear benefits for weight loss and glycaemic control, the sources indicate they may simultaneously offer short-term postoperative advantages…